Eric Falcand is the new CEO of Neopharmed Gentili

Home/Eric Falcand is the new CEO of Neopharmed Gentili

Eric Falcand is the new CEO of Neopharmed Gentili

Milan, October, 31st 2023 – Eric Falcand is the new CEO of Neopharmed Gentili, a pharmaceutical company specialised in the commercialisation of high-value therapeutic solutions, historically rooted in Italy and rapidly expanding beyond national borders, controlled by private equity firms Ardian and NB Renaissance in partnership with the Del Bono family. Falcand succeeds Alessandro Del Bono, who will continue as Executive Chairman.

Falcand’s appointment is consistent with Neopharmed Gentili’s development strategy, which was initiated in the 2000s and consolidated with the entry of major international players such as Ardian and NB Renaissance into the capital, with the aim of strengthening and further accelerating the company’s growth in Italy and Europe. Based in Milan, Italy, Neopharmed Gentili is today one of the main pharmaceutical companies operating in the Italian market. With one of the largest networks of medical representatives in Italy, boasts a leading position in several therapeutic areas such as cardiovascular and neurology, providing specialists and general practitioners with a wide range of therapeutic solutions.

Commenting on his appointment as CEO of Neopharmed Gentili, Eric Falcand said, “Neopharmed Gentili’s growth in Italy, particularly in recent years, has been remarkable. Neopharmed Gentili is a pharmaceutical company of great value, an example of competitiveness and attractiveness, mainly inside but also outside national borders. It is an honor for me to help accelerate the company’s international expansion, especially in the European Union, and to bring more and more innovative medicines to patients in Italy and Europe. I thank Alessandro del Bono and the Board of Directors for the trust and esteem shown by this appointment”.

Eric Falcand, born in France, has over 35 years of experience in the pharmaceutical industry, holding leadership positions at the helm of subsidiaries of multinational pharmaceutical companies and in the area of business development. Prior to joining Neopharmed Gentili, he was Vice President and Head of Business Development at Laboratoires Servier, where he did several transformational major M&A operations for the Group; and held several General Management positions, including Managing Director of Servier Russia and Servier UK. He was Head of Business Development and Licensing for Servier Monde in the United States. Prior to working at Servier, he was Commercial operations Manager at several companies including Synthelabo (Sanofi) and Virbac. Falcand holds a doctorate in Veterinary Medicine from Ecole Nationale Vétérinaire de Lyon and an MBA from EM Lyon Business School. He graduated from the Institut de Pharmacie Industrielle de Lyon.

“Falcand is a highly experienced manager with solid human and professional qualities and a strong international vision, qualities that make him the ideal figure to lead the company in its new phase of expansion. He will have the full support of the Board of Directors and I wish him a long path of success and great satisfaction at the helm of Neopharmed Gentili”, added Neopharmed Gentili Executive Chairman Alessandro Del Bono.


Neopharmed Gentili
Neopharmed Gentili is a pharmaceutical company born in Italy and historically rooted in its territory, expanding strongly beyond national borders thanks to a consolidated and reliable experience in M&A and Licensing transactions, especially with multinational partners. Research, responsibility, and care are the pillars that guide Neopharmed Gentili’s mission to improve the health and quality of life of patients, caregivers, and healthcare professionals. Neopharmed Gentili’s aspiration is to help people live as healthy and long-lived lives as possible, acting with ethical value and scientific precision, and offering solutions with high therapeutic value.

Media contacts:
Neopharmed Gentili’s Press Office
Value Relations
Angela Del Giudice
Mob. 392.6858392 |
Chiara Farroni
Mob. 331.4997375 |

Download the full press review
Download the press review of November 15th

Archive of news and press releases